Cases & Deals

  • Home
  • Practices
  • NewBridge Pharmaceuticals raises capital in Series C round

Share

NewBridge Pharmaceuticals raises capital in Series C round

May 2013

Client(s) NewBridge Pharmaceuticals Limited

Jones Day represented NewBridge Pharmaceuticals Limited, a specialty therapeutics company focused on pharmaceutical and biologics, in connection with its issuance of $48 million of Series C Convertible Preferred Stock in a private placement to Elan Corporation, Burrill & Company, and Kuwait Life Sciences Company.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.